

[1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES**Publication number:** WO0017201**Publication date:** 2000-03-30**Inventor:** SHIMADA JUNICHI (JP); IMMA HIRONORI (JP);
OSAKADA NAOTO (JP); SHIOZAKI SHIZUO (JP);
KANDA TOMOYUKI (JP); KUWANA YOSHIHISA (JP)**Applicant:** KYOWA HAKKO KOGYO KK (JP); SHIMADA JUNICHI
(JP); IMMA HIRONORI (JP); OSAKADA NAOTO (JP);
SHIOZAKI SHIZUO (JP); KANDA TOMOYUKI (JP);
KUWANA YOSHIHISA (JP)**Classification:****- International:** **A61P25/24; A61P25/28; C07D487/04; A61P25/00;
C07D487/00;** (IPC1-7): C07D487/04; A61K31/505**- European:** C07D487/04**Application number:** WO1999JP05176 19990922**Priority number(s):** JP19980267178 19980922**Also published as:** EP1116722 (A1)
 US6545000 (B1)
 EP1116722 (A4)
 CA2344828 (A1)
 EP1116722 (B1)
 DE69923197T (T2)
 AU756144B (B2)

less <<

Cited documents: WO9842711
 US5270311**Report a data error here****Abstract of WO0017201**

[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by general formula (I) or pharmacologically acceptable salts thereof which show adenosine A2A receptor antagonism, wherein R<1> represents heteroaryl, etc.; R<2> represents hydrogen, etc.; na and nb represent each an integer of 0 to 4; Q represents hydrogen, etc.; R<6> represents hydrogen, etc.; R<3> represents (i) hydroxy, (ii) hydroxy (lower alkyl), (iii) lower alkoxy, or (iv) imidazo[1,2-a]pyridyl, etc.; and R<4> and R<5> represent each lower alkyl or aryl, or R<4> and R<5> form together with the adjacent carbon atom a saturated carbon ring when R<3> is any of (i) to (iii); or R<4> and R<5> represent each hydrogen, lower alkyl or aryl, or R<4> and R<5> form together with the adjacent carbon atom a saturated carbon ring when R<3> is (iv).

Data supplied from the **esp@cenet** database - Worldwide